Veozah, as a selective estrogen receptor degrader, is contraindicated for use in specific populations, drug interactions, and dietary restrictions. Strict adherence to medication guidelines is necessary to ensure treatment safety.

1. Taboo population

(1) Pregnant women: Animal studies have shown embryotoxicity, and pregnancy status should be confirmed before medication. Efficient contraceptive measures should be taken during treatment and within one month after the last dose.

(2) Severe liver function impairment: Child Pugh C patients are contraindicated, while moderate to severe impairment (Child Pugh B) requires a 50% reduction and weekly monitoring of liver function.

(3) History of QT interval prolongation: Patients with baseline QTcF>480ms are contraindicated, and other QT interval prolonging drugs should be avoided in combination during treatment.

2. Forbidden foods

(1) Grapefruit products: can inhibit CYP3A4 metabolic enzymes, increase blood drug concentration by three times, and should be completely avoided during treatment.

(2) High calcium foods: Limit daily calcium intake to below 600mg to avoid affecting drug absorption efficiency.

(3) Alcoholic beverages: may increase the burden on liver function, it is recommended to quit drinking during treatment.

3. Restrictive conditions

(1) Cardiovascular monitoring: Electrocardiogram examination should be completed before treatment, and QT interval should be monitored weekly in the first month of treatment.

(2) Liver function requirements: ALT/AST must be<2.5 times ULN and bilirubin<1.5 times ULN before treatment can be initiated.

(3) Drug interactions: Strong CYP3A4 inhibitors need to be permanently discontinued for 5 half lives before non zolpidem treatment can begin.